

1 **Combined RT-qPCR and Pyrosequencing of a SARS-CoV-2 Spike Glycoprotein Polybasic**  
2 **Cleavage Motif Uncovers Rare Pediatric COVID-19 Spectrum Diseases of Unusual Presentation**

3 Patrick Philipp Weil<sup>1</sup>, Jacqueline Hentschel<sup>1</sup>, Frank Schult<sup>2</sup>, Anton Pembaur<sup>1</sup>, Beniam Ghebremedhin<sup>3</sup>,  
4 Olivier Mboma<sup>2</sup>, Andreas Heusch<sup>2</sup>, Anna-Christin Reuter<sup>1</sup>, Daniel Müller<sup>1</sup>, Stefan Wirth<sup>2</sup>, Malik  
5 Aydin<sup>4</sup>, Andreas C. W. Jenke<sup>5</sup>, Jan Postberg<sup>1,†</sup>

6 †corresponding author

7

8 <sup>1</sup>Clinical Molecular Genetics and Epigenetics, Faculty of Health, Centre for Biomedical Education &  
9 Research (ZBAF), Witten/Herdecke University, Alfred-Herrhausen-Str. 50, 58448 Witten, Germany

10 <sup>2</sup>HELIOS University Hospital Wuppertal, Children's Hospital, Centre for Clinical & Translational  
11 Research (CCTR), Witten/Herdecke University, Heusnerstr. 40, 42283 Wuppertal, Germany

12 <sup>3</sup>HELIOS University Hospital Wuppertal, Institute of Medical Laboratory Diagnostics, Centre for  
13 Clinical & Translational Research (CCTR), Witten/Herdecke University, Heusnerstr. 40, 42283  
14 Wuppertal, Germany

15 <sup>4</sup>HELIOS University Hospital Wuppertal, Experimental Pediatric Pneumology and Allergology,  
16 Children's Hospital, Centre for Clinical & Translational Research (CCTR), Witten/Herdecke  
17 University, Heusnerstr. 40, 42283 Wuppertal, Germany

18 <sup>5</sup>Klinikum Kassel, Zentrum für Kinder- und Jugendmedizin, Neonatologie und allgemeine Pädiatrie,  
19 Mönchebergstr. 41-43, 34125 Kassel, Germany

20

21

22

23

24

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 E-Mail addresses:

- 26 Patrick Philipp Weil: [patrick.weil@uni-wh.de](mailto:patrick.weil@uni-wh.de)
- 27 Jacqueline Hentschel: [jacqueline-hentschel@web.de](mailto:jacqueline-hentschel@web.de)
- 28 Frank Schult: [frank.schult@helios-gesundheit.de](mailto:frank.schult@helios-gesundheit.de)
- 29 Anton Pembaur: [anton.pembaur@uni-wh.de](mailto:anton.pembaur@uni-wh.de)
- 30 Beniam Ghebremedhin: [beniam.ghebremedhin@helios-gesundheit.de](mailto:beniam.ghebremedhin@helios-gesundheit.de)
- 31 Olivier Mboma: [olivier.mboma@helios-gesundheit.de](mailto:olivier.mboma@helios-gesundheit.de)
- 32 Andreas Heusch: [andreas.heusch@helios-gesundheit.de](mailto:andreas.heusch@helios-gesundheit.de)
- 33 Anna-Christin Reuter: [anna.christin.reuter@googlemail.com](mailto:anna.christin.reuter@googlemail.com)
- 34 Daniel Müller: [daniel\\_mueller\\_en@freenet.de](mailto:daniel_mueller_en@freenet.de)
- 35 Stefan Wirth: [stefan.wirth@helios-gesundheit.de](mailto:stefan.wirth@helios-gesundheit.de)
- 36 Malik Aydin: [malik.aydin@uni-wh.de](mailto:malik.aydin@uni-wh.de)
- 37 Andreas C. W. Jenke: [andreas.jenke@gnh.net](mailto:andreas.jenke@gnh.net)
- 38 Jan Postberg: [jan.postberg@uni-wh.de](mailto:jan.postberg@uni-wh.de)

39

40

41

42

43

44

45

46

47 **Abstract**

48 **Background:** Surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)  
49 infections is essential for the global containment measures with regard to the ongoing pandemic.  
50 Diagnostic gold standard is currently reverse transcription of the (+)RNA genome and subgenomic  
51 RNAs and subsequent quantitative polymerase chain reaction (RT-qPCR) from nasopharyngeal swabs  
52 or bronchoalveolar lavages. In order to further improve the diagnostic accuracy, particularly for the  
53 reliable discrimination between negative and false-negative specimens, we propose the combination of  
54 the RT-qPCR workflow with subsequent pyrosequencing of a S-gene amplicon. This extension might  
55 add important value mainly in cases with low SARS-CoV-2 load, where RT-qPCR alone can deliver  
56 conflicting results.

57 **Results:** We successfully established a combined RT-qPCR and S-gene pyrosequencing method  
58 which can be optionally exploited after routine diagnostics or for epidemiologic studies. This allows a  
59 more reliable interpretation of conflicting RT-qPCR results in specimens with relatively low viral  
60 loads and close to the detection limits of qPCR ( $C_T$  values  $>30$ ). After laboratory implementation and  
61 characterization of a best practice protocol we tested the combined method in a large pediatric cohort  
62 from two German medical centers ( $n=769$ ). Pyrosequencing after RT-qPCR enabled us to uncover 6  
63 previously unrecognized cases of pediatric SARS-CoV-2 associated diseases, partially exhibiting  
64 unusual and heterogeneous presentation. Moreover, it is notable that in the course of RT-  
65 qPCR/pyrosequencing method establishment we did not observe any case of false-positive diagnosis  
66 when confirmed SARS-CoV-2-positive specimens were used from foregoing routine testing.

67 **Conclusions:** The proposed protocol allows a specific and sensitive detection of SARS-CoV-2 close  
68 to the detection limits of RT-qPCR. Combined RT-qPCR/pyrosequencing does not negatively affect  
69 preceding RT-qPCR pipeline in SARS-CoV-2 diagnostics and can be optionally applied in routine to  
70 inspect conflicting RT-qPCR results.

71

72

73 **Keywords**

74 (+)RNA, COVID-19 surveillance, pediatric SARS-CoV-2-associated diseases, epidemiology

75

76 **Background**

77 As of April 26<sup>th</sup> 2020 at Helios University Hospital Wuppertal during a period of attenuation which  
78 followed the first peak phase of SARS-CoV-2 transmission in Germany only 2.3% of all laboratory-  
79 confirmed SARS-CoV-2-positive cases were children or teenagers (age group: 0-19 yrs). Nationwide  
80 as of September 8<sup>th</sup> 2020, the contribution of this age group to all SARS-CoV-2-positive cases had  
81 increased to 10.5% [1]. This development was in agreement with observations made globally, in  
82 particular in the US, whose population remains among the most affected of the SARS-CoV-2  
83 pandemic. Since then, a trend of weekly median age decline for persons with COVID-19-like illness  
84 was reported for an observation period between May 3<sup>rd</sup> – August 29<sup>th</sup> 2020. In particular, a steady  
85 increase of the percentage fraction of all confirmed SARS-CoV-2-positive cases for the 0-19 year olds  
86 was observed in the United States starting from 7.4% in May, 10.8% in June, 14.0% in July and  
87 preliminary being elevated up to 15.5% in August 2020 [2]. Reminiscent of this, at least since early  
88 autumn 2020 the 7-days-incidence for all pediatric age groups increased in similar ways as observed  
89 for most other age groups in Germany (Figure 1). As evidence is accumulating that pediatric  
90 presentation of SARS-CoV-2 associated diseases can possibly be more heterogeneous than adult  
91 COVID-19 there is an urgent need to recognize the full spectrum of unusual pediatric SARS-CoV-2-  
92 borne diseases. Reliable diagnosis of SARS-CoV-2 infection will eventually contribute to effective  
93 personalized treatment and optimized containment measures. To address this problem, we  
94 systematically screened two pediatric cohorts from Helios University Hospital Wuppertal (North  
95 Rhine-Westphalia, Western Germany) and Klinikum Kassel (Hessen, Central Germany). Therefore, in  
96 order to enable the re-examination of ambiguous SARS-CoV-2 (+)RNA RT-qPCR results, which  
97 particularly can occur in specimens with relatively low viral load, we developed and applied an  
98 improved assay that combines RT-qPCR and pyrosequencing. This strategy allows the reliable  
99 discrimination of SARS-CoV-2 from other human coronaviruses (HCoV) and can reduce the rate of

100 uncertain qPCR results, which might be influenced by several confounding factors, thus occasionally  
101 leading to false-negative qPCR results – particularly when PCR is close to its detection limits. Here,  
102 we provide a preliminary report of our epidemiological survey as well as a detailed protocol for an  
103 expanded SARS-CoV-2 (+)RNA detection method, which relies on the complementary exploitation of  
104 RT-qPCR and pyrosequencing of a genome fragment from the SARS-CoV-2 Spike glycoprotein  
105 polybasic cleavage motif. Following rigorous implementation, we applied the test on two pediatric  
106 cohorts from two German medical centers comprising 769 children in total (n=599 [Wuppertal];  
107 n=170 [Kassel]; 44% female/56% male; 53.6% 0-5 yrs, 28.7% 6-12 yrs, 17.7% 13-17 yrs) without  
108 indication for routine COVID-19 testing as defined by the WHO at time of presentation.

109

## 110 **Results**

111 *Design and implementation of a combined SARS-CoV-2 RT-qPCR/pyrosequencing test to complement*  
112 *established diagnostic workflows*

113 We targeted a region encoding a polybasic cleavage motif within the SARS-CoV-2 Spike glycoprotein  
114 (S). Multiple sequence alignment analyses demonstrate that this region could be a suitable  
115 differentiator between SARS-CoV-2, related coronaviruses from several animal host [3] as well as  
116 SARS-CoV-1, MERS-CoV and other HCoVs (Figure 2A.). For RT-qPCR we selected a set of forward  
117 primer (S<sub>pbc</sub>-CoV-2-F: 5'-GCAGGCTGTTTAATAGGGGC-3') and 5'-biotinylated reverse primer  
118 (S<sub>pbc</sub>-CoV-2-R<sub>BIO</sub>: 5'-biotin-TEG-ACCAAGTGACATAGTGTTAGGCA-3'), since Primer-BLAST  
119 (<https://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi>) query confirmed the probable suitability  
120 of the selected primer set predicting a 162 bp SARS-CoV-2-specific amplicon matching perfectly to  
121 the complete reported list of SARS-CoV-2 isolates. As probe for TaqMan qPCR we used 5'-HEX-  
122 ATTGGTGCAGGTATATGCGCTAGTTATC-BBQ-650-3' (S<sub>pbc</sub>-CoV-2-P). Without carrying the 5'-  
123 /3'-modifications we selected the same oligonucleotide sequence for the pyrosequencing primer (S<sub>pbc</sub>-  
124 CoV-2-S) (Figure 2B.; Table S1).

125 For all tests we used specimens, which underwent routine COVID-19 diagnostic testing and were pre-  
126 categorized 'confirmed SARS-CoV-2-positive' or 'negative'. For comparison we used the full set of

127 ‘Charité protocol’ amplicon targets (RdRP, E, N) [4] (Table S1). Before RT-qPCR, total RNA was  
128 purified from 250 µL of nasopharyngeal swabs or bronchoalveolar lavage specimens using the  
129 guanidinium isothiocyanate (GITC) extraction method. Besides, due to RT-qPCR reagent  
130 manufacturer’s recommendation, we tested whether the RNA purification step could be dispensable.  
131 Briefly, using stabilized raw specimens from SARS-CoV-2 as RT-qPCR templates, results from the  
132 same specimens using purified RNA could only be matched in some cases (Figure S1). Therefore, we  
133 neglected this approach during our successive experiments.

134 Reverse transcription and subsequent amplification of cDNA were carried out using universal one-step  
135 RT-qPCR reaction mastermixes. A detailed protocol including recommended reagents is provided in  
136 the Methods section. Quantitative PCR programs often use an excess of cycling steps, frequently  
137 leading to the incremental enrichment of unspecific byproducts during later cycles. With respect to the  
138 quality of subsequent pyrosequencing, we aimed on the optimization of PCR cycle numbers for  
139 singleplex, duplex and triplex PCR approaches. We determined that 36 sequential qPCR cycles of  
140 denaturation, annealing and elongation were a good compromise with respect to multiple prudential  
141 reason: 1. Typically, for different amplicons we observed that the cycle threshold ( $C_T$ ) limit for the  
142 faithful discrimination between positive and negative samples was below a  $C_T$  of 35 (Figure 3).  
143 Consistently, semi-quantitative PCR and subsequent electrophoresis resulted in a specific 162 bp band  
144 and no or occasionally few weak byproducts (Figure S2A). 2. For approx. 35 or more cycles we  
145 observed accelerated curve increments and thresholds crossing also for negative samples and no-  
146 template controls indicating ongoing amplification of PCR byproducts. Using an excess of PCR  
147 cycles, multiple unspecific byproducts and DNA smear of higher molecular weight are observable in  
148 confirmed positive and negative specimens (Figure S2B).

149 Besides an excess of PCR cycles, we identified multiplex PCR approaches where more than one  
150 amplicon is targeted by multiple primer sets in one PCR reaction as another possible confounding  
151 factor influencing PCR quality and successive pyrosequencing. To test this hypothesis, we performed  
152 triplex RT-qPCR reactions by simultaneously using RdRP, Orf E and Orf N amplicon targets. Semi-  
153 quantitative analyses by agarose gel electrophoresis demonstrate that numerous low and high  
154 molecular weight byproducts were amplified in both cases when RNA from confirmed SARS-CoV-2-

155 positive specimens or negative specimens was used (Figure S3). Since we assumed that biotinylated  
156 byproducts could massively impair successive pyrosequencing we decided to neglect triplex  
157 approaches for the intended combinatorial use of RT-qPCR. With emphasis on the SARS-CoV-2 S-  
158 gene amplicon we instead aimed to compare the specificities, efficiencies and sensitivities of  
159 singleplex RT-qPCR vs. duplex RT-qPCR. In order to further characterize the performance of the  
160 SARS-CoV-2 S-gene amplicon target and to select the best additional amplicon for a duplex  
161 approach, we performed comprehensive RT-qPCR tests using the S-gene, Orf E, Orf N and RdRP as  
162 amplicon targets and using serially diluted specimens from the same confirmed SARS-CoV-2-positive  
163 specimens for all RT-qPCR reactions. Figure 3 illustrates the performance of different qPCR assays  
164 for one representative SARS-CoV-2-positive nasopharyngeal specimen. Taken together, TaqMan RT-  
165 qPCR for both the S-gene amplicon and the Orf E amplicon with similar sensitivity as indicated by  
166 low  $\Delta C_T$  between S-gene and Orf E in singleplex reactions. Further, we deduced from a series of serial  
167 template dilutions that amplification efficiency for both the S-gene target and the Orf E target is high  
168 but weakens between  $C_T=30$  and  $C_T=35$ . In duplex RT-qPCR assays targeting simultaneously the S-  
169 gene target and Orf E in one reaction no notable changes in sensitivity or qPCR efficiency were seen  
170 (Figure 3A). With respect to efficiency also the Orf N amplicon target performed well, but its  
171 sensitivity lagged behind as indicated by a large  $\Delta C_T$  when compared to Orf E (Figure 3B). In stark  
172 contrast, the RdRP amplicon frequently performed volatile and appeared to lag behind the sensitivities  
173 of all other amplicons in the majority of specimens examines - as in the illustrated case, where even  
174 the curve for the undiluted sample did not cross the predefined threshold (Figure 3B). Therefore, apart  
175 from a singleplex S-gene RT-qPCR/pyrosequencing approach, we considered a duplex (S-gene and  
176 Orf E) RT-qPCR/S-gene pyrosequencing approach as a promising combination for the faithful  
177 detection of active SARS-CoV-2 infections.

178 To test this hypothesis, we performed subsequent pyrosequencing of the biotinylated single-stranded  
179 S-gene amplicon using the same serial dilution samples described above (Figure 4). The proposed  
180 pyrosequencing approach could theoretically allow to read a SARS-CoV-2 (+)RNA-specific sequence  
181 fragment of 55 nt. Using the undiluted sample from the singleplex S-gene amplicon RT-qPCR  
182 reaction, we achieved an unbiased 53 nt sequence fragment, which could unambiguously be assigned

183 to the SARS-CoV-2 reference genome. Successive serial dilutions led to modest enrichment of  
184 miscalled bases in the resulting pyrogram, but still allowed the faithful assignment of the called  
185 sequence to SARS-CoV-2 up to a corresponding approx.  $C_T \approx 30$ . Serial dilutions were gradually  
186 accompanied by a weakening of pyrogram-signal strength and a decreased signal-to-noise ratio.  
187 Automated basecalling of the SARS-CoV-2 sequence failed frequently for samples with  $C_T > 30$ .  
188 However, for a range between  $C_T \approx 30$  and  $C_T \approx 35$  the most adverse reason counteracting SARS-CoV-2  
189 sequence recognition appeared to be the decremental signal-to-noise ratio, which led to incremental  
190 false-positive calling of repetitive bases. The illustrated examples suggest the presence of signals  
191 encoding the targeted SARS-CoV-2, which could be separable from the threshold noise signals. S-  
192 gene pyrosequencing performed equally well, when a duplex (S-gene and Orf E) RT-qPCR was  
193 conducted priorly (Figure 4). We noted a tendency of slightly increasing numbers of missing or excess  
194 basecalls towards the 3'-end of the pyrosequenced SARS-CoV-2 fragment. As a preliminary  
195 conclusion we first highlight that the proposed pyrosequencing approach does not negatively affect  
196 preceding RT-qPCR pipeline in SARS-CoV-2 diagnostics. Second, it adds important value to RT-  
197 qPCR, where this method alone delivers conflicting results, particularly close to the detection limits  
198 qPCR ( $C_T$  values  $> 30$ ). In RT-qPCR alone even negative samples frequently exhibit curves crossing  
199 the threshold within a range between  $C_T \approx 30$  and  $C_T \approx 35$  complicating mainly the reliable  
200 discrimination between PCR-negatives and PCR-false-negatives.

201 In a next step, after protocol implementation we checked the sustainability of the combined RT-  
202 qPCR/pyrosequencing method in an epidemiological field test.

203  
204 *Performance of the combined methods of RT-qPCR and pyrosequencing in epidemiologic field study*  
205 *on pediatric patients from two German medical centers*

206 We tested our combined RT-qPCR/pyrosequencing method on two pediatric cohorts from two German  
207 medical centers comprising 769 children in total ( $n=599$  [Wuppertal];  $n=170$  [Kassel], who had no  
208 indication for routine SARS-CoV-2 testing at presentation according to WHO criteria. After initial S-  
209 gene amplicon detection, we used at least ORF E as backup amplicon as well as ORF N and RdRP in



210 some cases. Even for RT-qPCR results with relatively high  $C_T$  values, successive pyrosequencing  
211 could unambiguously confirm SARS-CoV-2 infections. Where possible, we investigated SARS-CoV-  
212 2-specific immunity. In sum, using retrospectively the combined RT-qPCR/pyrosequencing method,  
213 we confirmed 6 pediatric cases of SARS-CoV-2-associated diseases among the entire cohort  
214 exhibiting heterogenous presentation:

215

216 *Brief case report 1. Adolescent male with sore throat (age group 13-17 years)*

217 During the 2020 spring peak of incremental SARS-CoV-2 transmission at end of April an  
218 adolescent male patient presented at the emergency department in slightly reduced general  
219 condition with 37.5°C body temperature and reddened throat. The clinical examination was  
220 otherwise completely normal. At time of presentation the patient did not fulfill the criteria for  
221 routine SARS-CoV-2 testing. The specimen was incidentally tested and classified potentially  
222 being SARS-CoV-2-positive in the course of our serial examination of the Wuppertal pediatric  
223 cohort using the newly developed S-gene amplicon target for singleplex RT-qPCR (repetitive  $C_T$   
224 values: 25.47 and 25.33). The result was unambiguously confirmed by pyrosequencing and  
225 backed-up by positive RT-qPCR results using the ORF E ( $C_T$  value: 23.78), ORF N ( $C_T$  value:  
226 27.47) and RdRP ( $C_T$  value: 31.23) amplicon targets. Three months after first presentation, the  
227 patient was positive for SARS-CoV-2-specific antibodies (34.20 +; Roche), strongly suggesting  
228 that the boy underwent an inconspicuous course of SARS-CoV-2 infection.

229

230 *Brief case report 2. Female toddler with Multisystem Inflammatory Syndrome in Children (MIS-C)*  
231 *(age group 1-3 years)*

232 A female toddler was admitted to the hospital with altered general status and undulant fever. The  
233 initial physical examination revealed tonsillitis without any cardio-respiratory affections.  
234 Laboratory analyses revealed highly elevated C reactive protein (24.0 mg/dL [normal<0.5]) with  
235 almost normal interleukin-6 levels at 55.2 pg/ml. Interestingly, no leukocytosis or lymphopenia  
236 were diagnosed. In the clinical course, symptoms reminiscent of Kawasaki-like disease included

237 persistent fever, bilateral conjunctivitis, cheilitis and a maculopapular exanthema. Furthermore,  
238 echocardiography exhibited enlargement of the left coronary artery and pericardial effusion  
239 (Figure S4A). Cardiac related blood parameters were within the normal ranges. Under the  
240 suspicion of Multisystem Inflammatory Syndrome in Children (MIS-C) associated with COVID-  
241 19 [5, 6] she was given intravenous gamma globulins (2 g/kg), prednisolone (2 mg/kg) and  
242 acetylsalicylic acid (50 mg/kg) at day five which resulted in rapid improvement of the girl's  
243 general status. Apyrexia was achieved on day seven. At day ten of hospitalization SARS-CoV-2  
244 RT-qPCR tests were negative.

245

246 *Brief case report 3. Pre-school boy with high grade fever (age group 4-6 years)*

247 A pre-school boy with bowel disease history presented at the paediatric emergency department  
248 with a history of one day high-grade fever. Clinical examination did not reveal a specific focus. He  
249 was admitted for suspected sepsis and started on intravenous antibiotics. After one day the  
250 condition of the patient and the inflammatory markers improved. The blood culture confirmed a  
251 bacterial bloodstream infection (BSI). On day 2 of inpatient care, the patient developed facial,  
252 neck and upper limb oedema, vein distention in the upper chest and shortness of breath suggestive  
253 of superior vena cava (SVC) syndrome. CT-angiography of the chest confirmed this diagnosis  
254 demonstrating a stenosis of the SVC (lumen diameter 1.4 mm), adjacent thrombosis and multiple  
255 collateral veins draining towards an enlarged vena azygos. Retrospectively, we uncovered a co-  
256 infection with SARS-CoV-2, which presumably was temporally associated with the BSI. Mean  $C_T$   
257 value of repetitive RT-qPCR was relatively high ( $C_T$ : 34.06) with conspicuous curve shape.  
258 SARS-CoV-2 was unambiguously confirmed by pyrosequencing.

259

260 *Brief case report 4. Male secondary school child with isolated swollen neck lymph node (age group*  
261 *10-12 years)*

262 A male prepubescent secondary school child presented to the emergency department in late March  
263 2020 complaining about a ‘bump’ behind his left ear. Otherwise, he was completely  
264 asymptomatic. Clinical examination revealed a non-tender swelling behind the left ear of about 7-  
265 8 mm in diameter which was interpreted as an enlarged lymph node as well as slightly enlarged  
266 cervical lymph nodes on the same site. No cardiac, neurological, pulmonary or gastrointestinal  
267 abnormalities were note and the patient was sent home. At time of presentation the patient did not  
268 fulfill the criteria for routine SARS-CoV-2 testing. Mean  $C_T$  value of repetitive RT-qPCR was  
269 relatively high ( $C_T$ : 35.56) with conspicuous curve shape. SARS-CoV-2 was unambiguously  
270 confirmed by pyrosequencing.

271

272 *Brief case report 5.: Female adolescent with EBV-like disease (age group 14-17 years)*

273 A female adolescent presented late in March 2020 with high fever up to 40.2°C, hepatomegaly and  
274 tonsillitis. She was found to have acute Epstein-Barr-Virus infection and was discharged home 3  
275 days later without fever in good general condition. Nine days later she presented again with low  
276 temperature up 38.4°C, general malaise and slightly increased liver enzymes. All other diagnostic  
277 test at that time – including abdominal ultrasound, laboratory studies and urine analysis – were  
278 normal. During the following two days she improved spontaneously and was discharged home. At  
279 that time symptoms were believed to be associated with the recent EBV infection. No SARS-CoV-  
280 2 testing was performed since the patient did not fulfill the clinical criteria for suspected Covid-19  
281 at that time. Mean  $C_T$  value of repetitive RT-qPCR was relatively high ( $C_T$ : 32.80) with  
282 conspicuous curve shape. SARS-CoV-2 was unambiguously confirmed by pyrosequencing. In  
283 October 2020 the patient was found to have IgA and IgG antibodies against SARS-CoV-2 (SARS-  
284 CoV-2 ELISA, EUROIMMUN).

285

286 *Brief case report 6: Male toddler with generalized febrile seizure (age group 1-3 years)*

287 A male toddler was admitted late in March 2020 due to a generalized febrile seizure which  
288 spontaneously resolved after 4 min. The parents reported that he developed a low-grade fever up

289 to 38.6°C several hours prior the event. He also had moderate diarrhoea with three to four pulpy  
290 bowel movements per days and vomited three times on the day of admission. The parents did not  
291 note any mucous or blood. On admission, clinical examination was unremarkable except for mild  
292 pharyngitis, intestinal hyperperistalsis and mild dehydration. Differential blood count, liver  
293 enzymes, blood gases, electrolytes, C-reactive protein as well as urine analyses (except for ketone  
294 bodies) were all normal. Stool tests came back negative for Rotavirus, Norovirus, Shigella,  
295 Campylobacter, Salmonella and Yersinia. The patient received intravenous fluids and was  
296 discharged two days later without fever in good clinical condition. At that time the patient was  
297 diagnosed with mild gastroenteritis and secondary uncomplicated generalized febrile seizure. RT-  
298 qPCR and pyrosequencing confirmed a SARS-CoV-2 infection.

299

## 300 **Discussion**

301 *Numerous confounding factors influence the outcome of RT-qPCR in SARS-CoV-2 diagnostics*

302 Whereas reverse transcription and subsequent quantitative PCR (RT-qPCR) are key methods for the  
303 detection of SARS-CoV-2 and local as well as global pandemic surveillance, it is well known that  
304 several confounding factors can lead to false-negative results. It seems clear that the time course of  
305 SARS-CoV-2 load in the days after infection massively influences the predictive value of the RT-  
306 qPCR tests. A recent study discovered a median false-negative rate as high as 38% (CI, 18% to 65%)  
307 even at the day of symptom onset, although concomitantly SARS-CoV-2 load seems to be close to its  
308 highest levels. Moreover, few days before and after symptom onset the false-negative SARS-CoV-2  
309 discovery rate by RT-qPCR seems to worsen dramatically [7]. Besides the time point of specimens  
310 sampling post-infection, heterogeneities in specimens sampling technique, transportation, storage  
311 conditions, nucleic acids purification, laboratory equipment, staff experience but also RT-qPCR  
312 conditions might be among the most important factors influencing test qualities. Very early in 2020  
313 the WHO started to disseminate the ‘Charité protocol’ for the diagnostic detection of SARS-CoV-2 by  
314 RT-qPCR. Therein, a strategy for the combinatorial use of PCR primers (#name\_F/#name\_R) and  
315 TaqMan probes (#name\_P) was described with amplicon targets in the SARS-CoV-2 RNA-dependent

316 RNA polymerase (RdRP) gene as well as in the open reading frames (ORF) E and N  
317 (E\_Sarbeco\_F/\_P1/\_R; N\_Sarbeco\_F/\_P/\_R; RdRP\_SARSr-F/\_P2/\_R) (Table S1) [8]. As of  
318 November 10<sup>th</sup> 2020, PubMed reported 976 citations for this article, suggesting the widespread use of  
319 the contained protocols for SARS-CoV-2 detection in association with the global attempt of pandemic  
320 surveillance and containment measures. However, several RT-qPCR assays are being used by clinical,  
321 research and public health laboratories and some studies suggest that there could be relevant  
322 differences in the efficiencies, sensitivities and specificities of the different amplicon targets under  
323 different laboratory conditions, in particular for the RdRP\_SARSr amplicon [9, 10]. Remarkably, RT-  
324 qPCR does not exclusively target genomic SARS-CoV-2 amplicons, but (dependent on the selected  
325 primers) logically also can amplify the transcribed shorter subgenomic mRNAs (sgRNAs). At least  
326 two deep-sequencing studies on coronavirus transcriptomes (HCoV-229E and SARS-CoV-2) reported  
327 a dominant coverage of mapped reads towards the 3'-end of the SARS-CoV-2 genome, possibly due  
328 to an abundance of the sgRNAs [11, 12]. Notably, these sgRNAs encode conserved structural proteins  
329 with the Spike glycoprotein (S), the envelope protein (E) and the nucleocapsid protein (N) being  
330 among them. For the nonstructural RdRP, in contrast, the genomic (+)RNA itself becomes expressed  
331 by genome translation and ribosomal frameshifting [13]. The coverage of mapped reads was  
332 comparatively lower for the RdRP encoding ORF1b as well as the 5'-proximal ORF1a than for the  
333 sgRNA encoding 3'-end. However, it remains poorly understood so far how oscillations in the  
334 expression of SARS-CoV-2 sgRNAs might contribute to the observed variations in qPCR testing.  
335 Therefore, we aimed to develop a confirmatory test for a stably expressed SARS-CoV-2 sgRNA  
336 amplicon target that can complement RT-qPCR strategies without disturbing established and  
337 automatable laboratory workflows. In particular, we intended to develop a pyrosequencing assay that  
338 would allow, subsequent to RT-qPCR, the categorical confirmation of SARS-CoV-2 infections in  
339 acute cases, where the clinical suspicion is high, but the SARS-CoV-2 infection cannot be ruled out by  
340 RT-qPCR alone. The proposed pyrosequencing approach does not negatively affect preceding RT-  
341 qPCR pipelines in SARS-CoV-2 diagnostics and can therefore add important value to RT-qPCR,  
342 where this method alone delivers conflicting results. Particularly, this can happen close to the  
343 detection limits qPCR, practically  $C_T$  values  $>30$ . Frequently, even negative samples exhibit curves

344 crossing the threshold within a range between  $C_T \approx 30$  and  $C_T \approx 35$  complicating the reliable  
345 discrimination between PCR-negative and PCR-false-negative specimens. Theoretically, also PCR-  
346 false-positives results could happen, but practically we did not observe any case of false-positive  
347 diagnosis within the numerous confirmed SARS-CoV-2-positive specimens from clinical routine  
348 testing used during the entire phase of RT-qPCR/pyrosequencing development. Here, we have shown  
349 that pyrosequencing can be a powerful complementary method of specific and sensitive SARS-CoV-2  
350 case confirmation, without affecting foregoing routine RT-qPCR. But even here, lower template  
351 concentrations led to the occasional occurrence of miscalled bases (missing bases: red triangle; excess  
352 bases: blue triangle) and gradual convergence of signal and noise peaks. Gradually, this led to  
353 increasingly misinterpreted peak heights particularly for nucleotide repeat motifs and lower  
354 complexity motifs. Whereas concomitantly, automated basecalling gradually failed to separate signal  
355 from noise, the SARS-CoV-2 specific sequence could be identified by manual inspection much longer.  
356 Manufacturer's adaptations to the basecalling algorithm could lead to an improvement. Moreover, for  
357 each nucleotide position we used an 'open' pyrosequencing dispensation order (assuming N [i.e. C, G,  
358 A or T] as possible nucleotides for each position) in order to detect variable positions. From the end  
359 users' sides, a SARS-CoV-2 specific dispensation order could possibly lead to an improved automated  
360 basecalling sensitivity. However, being aware that any further sample treatment in laboratory routine  
361 would impair the necessary high throughput testing, in particular in the course of SARS-CoV-2  
362 surveillance, we see the main application opportunities for combined RT-qPCR/pyrosequencing in  
363 research for retrospective epidemiology studies, longitudinal studies of the course of COVID-19 cases  
364 and studies on pathomechanisms, in particular if they aim on systemic surveys of virus-host  
365 interaction.

366

367 *Several cases with unusual presentations of pediatric SARS-CoV-2-infections were uncovered*

368 Exemplarily for the implementation of the developed experimental pipeline for an epidemiological  
369 survey, we conducted a field study in search for SARS-CoV-2 infected patients without obvious  
370 common SARS-CoV-2 associated symptoms, since the majority of cases pediatric SARS-CoV-2  
371 infections develop only very mild disease courses [14]. In a very recent UK national cohort study on

372 neonatal SARS-CoV-2 infection 66 SARS-CoV-2-positive babies could be identified, who at day of  
373 presentation exhibited hyperthermia, poor feeding, vomiting, coryza, other respiratory signs and  
374 lethargy as the most common signs of infection or, respectively, no signs of infection at all [15]. On  
375 the other hand, an unknown fraction of SARS-CoV-2 infections in childhood seem to fundamentally  
376 differ from adults and can be more heterogeneous in their presentation. The most striking example is  
377 Multisystem Inflammatory Syndrome in Children (MIS-C), a rare SARS-CoV-2-induced Kawasaki-  
378 like hyperinflammatory syndrome [5, 6]. Another recent study reports that children and adults can  
379 exhibit a very different antibody responses upon SARS-CoV-2-infections across the clinical spectrum  
380 of associated diseases, which do not obligatorily match the adult COVID-19 spectrum [16].  
381 Necessarily, the association unusual symptoms with acute infections will contribute to our  
382 understanding about the heterogeneity of SARS-CoV-2-borne diseases in general and particularly in  
383 children. Using two large pediatric cohorts for a field study, we have successfully demonstrated in this  
384 study that combined RT-qPCR/pyrosequencing is a reliable tool that allows the faithful confirmation  
385 of less distinctive or asymptomatic cases with SARS-CoV-2 infection close to the detection limits of  
386 RT-qPCR. Here, the determination of a SARS-CoV-2-specific sequence fragment can decisively help  
387 to improve reliability for cases where the discrimination between negative/false-negative RT-qPCR  
388 reports can be important. Whereas this might possibly be of subordinate importance for practical  
389 containment measures because low viral load could be associated with low infectiousness, it can  
390 contribute to recognize the still probably underestimated extent of SARS-CoV-2 prevalence and  
391 associated mild or asymptomatic presentations. In particular, from a large cohort of children who did  
392 not fulfil the criteria for SARS-CoV-2 testing we have retrospectively identified 6 cases of SARS-  
393 CoV-2 related symptoms. The identification and characterization of this cases will thus contribute to  
394 the understanding of the full heterogenous picture of presentation of SARS-CoV-2 infections.

395

## 396 **Conclusions**

397 The proposed protocol allows the specific and sensitive detection of SARS-CoV-2 close to the  
398 detection limits of RT-qPCR. Combined RT-qPCR/pyrosequencing does not negatively affect

399 preceding RT-qPCR pipeline in SARS-CoV-2 diagnostics and can be optionally applied in routine to  
400 inspect conflicting RT-qPCR results. Particularly in research, the proposed workflow can valuably  
401 contribute to identify and characterize the unknown fraction of cases of SARS-CoV-2 -associated  
402 diseases in childhood, which can fundamentally differ from adults and can be more heterogeneous in  
403 their presentation.

404

## 405 **Methods**

### 406 *Sampling of pediatric and adult human specimens*

407 Nasopharyngeal swabs or bronchoalveolar lavage specimens were collected at Helios University  
408 Hospital Wuppertal (North Rhine-Westphalia, Western Germany) and Klinikum Kassel (Hessen,  
409 Central Germany) with approval of the Witten/Herdecke University ethics committee (covered by  
410 ‘CoronaKids’ [No. 61/2020] and No. 160/2020 for the use of routinely sampled and confirmed  
411 specimens for RT-qPCR/pyrosequencing method establishment). Informed written consent was  
412 obtained from legal guardians of the involved children. All work has been conducted according to the  
413 principles expressed in the Declaration of Helsinki.

414

### 415 *Storage and nucleic acids isolation*

416 Specimens included nasopharyngeal swabs or bronchoalveolar lavage specimens, which underwent  
417 routine COVID-19 diagnostic testing. Pediatric cohort specimens were collected using brushes from  
418 the Gentra Puregene Buccal Cell Kit (100) (Qiagen, Cat. No. 158845) and then stabilized in 500  $\mu$ L  
419 RNeasy Lysis Buffer (Thermo Fisher Scientific, Cat. No. AM7021). All specimens were stocked at  $-80^{\circ}\text{C}$ .  
420 Total RNA was purified from 250  $\mu$ L liquid specimen using 750  $\mu$ L QIAzol lysis reagent (Qiagen,  
421 Cat. No. 158845) upon manufacturer’s recommendations. RNA quality and quantity were assessed by  
422 microcapillary electrophoresis using the Small RNA kit (Agilent, Cat. No. 5067-1548) and the Agilent  
423 Bioanalyzer 2100 instrument.



424 Importantly, we determined that long term storage (to date, up to 9 months) under these conditions  
425 allows unbiased RT-qPCR analyses. However, we note that repeated freeze and thaw cycles of stored  
426 specimens as well as purified RNA affect sample quality and result in gradually increasing  $C_T$  values.

427

#### 428 *RT-qPCR*

429 Quantitative analyses of SARS-CoV-2 (+)RNA from human specimen was carried out combining  
430 reverse transcription and qPCR in a one-step protocol using Luna Universal Probe One-Step RT-qPCR  
431 Kit w/o ROX (New England Biolabs, Cat. No. E3007E) on a Corbett Rotor-Gene 6000 instrument.  
432 Primers and probes are described above and listed (Table S1). Per reaction, each primer and probes  
433 were used at 500 nM. 2  $\mu$ L of purified template RNA were used for each single reaction volume of  
434 20  $\mu$ L. RT-qPCR conditions were as follows: Reverse transcription (RT) (60°C/30 min), initial  
435 denaturation and Hot Start *Taq* polymerase activation 95°C/2 min, cycling (36x[denaturation  
436 95°C/15 s, extension 60°C/30 s]) and final extension 68°C/5 min. 36 qPCR cycles were determined to  
437 largely avoid multiple unspecific byproducts and giving rise of sufficient amounts of biotinylated  
438 amplicon for subsequent pyrosequencing purposes. This amplicon could be used directly for  
439 pyrosequencing.

440

#### 441 *Pyrosequencing*

442 Pyrosequencing of the biotinylated single-stranded S-gene amplicon was performed on a  
443 PyroMark Q48 Autoprep device (Qiagen). The PyroMark Q48 Advanced CpG Reagents (4x 48)  
444 (Qiagen, Cat. No. 974002) including dNTPs, substrates and enzymes are loaded to the assigned  
445 cartridges with volumes being adapted to the assay requirements. The designed approach theoretically  
446 allows to read a SARS-CoV-2 (+)RNA-specific sequence fragment of 55 nt. Further, the sequencing  
447 primer ( $S_{\text{pbcc-CoV-2-S}}$ ) was added to the assigned cartridge in a predetermined volume. 10  $\mu$ L of each  
448 RT-qPCR amplicon were loaded to each well of a PyroMark Q48 Disc and then 3  $\mu$ L PyroMark Q48  
449 Magnetic Beads (300) (Qiagen, Cat. No. 974203) were added to each reaction. The sequencing

450 reaction was initiated after denaturation and subsequent magnetic bead capture of the biotinylated  
451 single-stranded S-gene amplicon. The pyrosequencing software records the light signals corresponding  
452 to each well in the PyroMark Q48 Disc and saves the data graphically. Basecalled pyrograms were  
453 then manually inspected and analyzed for SARS-CoV-2 sequence verification.

454

#### 455 **List of abbreviations**

456 (+)RNA (sense polarity [single-stranded] ribonucleic acid), CI (confidence interval), COVID-19  
457 (coronavirus disease 2019), MERS (Middle East respiratory syndrome), C<sub>T</sub> (cycle threshold), ORF  
458 (open reading frame), RdRP (RNA-dependent RNA polymerase), RT-qPCR (reverse transcription-  
459 quantitative polymerase chain reaction, SARS-CoV-1 (SARS-CoV-2 (severe acute respiratory  
460 syndrome coronavirus 1), SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), sgRNA  
461 (subgenomic RNA), *Taq* (*Thermus aquaticus*)

462

#### 463 **Declarations**

##### 464 *Ethics approval and consent to participate*

465 For the collection and use of specimens at Helios University Hospital Wuppertal (North Rhine-  
466 Westphalia, Western Germany) and Klinikum Kassel (Hessen, Central Germany) with obtained  
467 approval of the Witten/Herdecke University Ethics board (covered by ‘CoronaKids’ [No. 61/2020]  
468 and No. 160/2020 for the use of routinely sampled and confirmed specimens for RT-  
469 qPCR/pyrosequencing method establishment). All work has been conducted according to the  
470 principles expressed in the Declaration of Helsinki.

471

##### 472 *Consent for publication*

473 Informed written consent was obtained from legal guardians of the involved children.

474

475 *Availability of data and material*

476 Not applicable

477

478 *Competing interests*

479 There are no conflicting interests for none of the authors, which need declaration.

480

481 *Funding*

482 The study was financed by own institutional means.

483

484 *Authors' contributions*

485 PPW helped to design the methodology and helped to write the paper. PPW, JH and JP established  
486 RT-qPCR tests and pyrosequencing. FS with the help of JH conducted the tests on the pediatric cohort.  
487 AP supported RT-qPCR works and alternative sequencing methods. BG and JO provided specimens,  
488 technical support and helped in the study design and data interpretation. OM, AH and MA  
489 characterized the Wuppertal case of a Multisystem Inflammatory Syndrome in Children (MIS-  
490 C)/Kawasaki-like syndrome. ACR and DM supported sample preparation and RT-qPCR  
491 establishment. SW and MA designed, coordinated and contributed to data analyses with respect to the  
492 Wuppertal cohort study. ACWJ participated in the design of the pediatric cohort study, contributed  
493 specimens, helped in data interpretation, provided clinical case characterizations from Kassel and  
494 helped to write the paper. JP designed the RT-qPCR/pyrosequencing study concept, contributed to the  
495 pediatric cohort study, supervised the entire study, took part in protocol establishment, interpreted the  
496 data and wrote the paper.

497

498 *Acknowledgements*

499 We thank Prof. Parviz Ahmad-Nejad (Institute of Medical Laboratory Diagnostics, Helios University  
500 hospital Wuppertal) and the involved staff, in particularly Jennifer Ortelt, Anna Wagener and Petra  
501 Menk, for providing specimens for method establishment and for the seamless collaboration.

502

## 503 References


- 504 1. **Coronavirus Disease 2019 (COVID-19) - Daily Situation Report of the Robert Koch Institute**  
505 [[https://www.rki.de/DE/Content/InfAZ/N/Neuartiges\\_Coronavirus/Situationsberichte/Sept\\_2020/2020-09-08-en.pdf?blob=publicationFile](https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Sept_2020/2020-09-08-en.pdf?blob=publicationFile)]
- 507 2. Boehmer TK, DeVies J, Caruso E, van Santen KL, Tang S, Black CL, Hartnett KP, Kite-Powell A,  
508 Dietz S, Lozier M *et al*: **Changing Age Distribution of the COVID-19 Pandemic - United States,**  
509 **May-August 2020.** *MMWR Morb Mortal Wkly Rep* 2020, **69**(39):1404-1409.
- 510 3. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF: **The proximal origin of SARS-CoV-**  
511 **2.** *Nat Med* 2020, **26**(4):450-452.
- 512 4. Weil PP, Reincke S, Hirsch CA, Aydin M, Scholz J, Jönsson F, Hagedorn C, Nguyen DN, Jiang P,  
513 Pembaur A *et al*: **Uptake of xenobiotic milk induces microRNA profile changes in the**  
514 **neonate intestine.** *Manuscript in preparation* 2020.
- 515 5. Licciardi F, Pruccoli G, Denina M, Parodi E, Taglietto M, Rosati S, Montin D: **SARS-CoV-2-**  
516 **Induced Kawasaki-Like Hyperinflammatory Syndrome: A Novel COVID Phenotype in**  
517 **Children.** *Pediatrics* 2020, **146**(2).
- 518 6. Ouldali N, Pouletty M, Mariani P, Beyler C, Blachier A, Bonacorsi S, Danis K, Chomton M,  
519 Maurice L, Le Bourgeois F *et al*: **Emergence of Kawasaki disease related to SARS-CoV-2**  
520 **infection in an epicentre of the French COVID-19 epidemic: a time-series analysis.** *Lancet*  
521 *Child Adolesc Health* 2020, **4**(9):662-668.
- 522 7. Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J: **Variation in False-Negative Rate of**  
523 **Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since**  
524 **Exposure.** *Ann Intern Med* 2020, **173**(4):262-267.
- 525 8. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brunink S,  
526 Schneider J, Schmidt ML *et al*: **Detection of 2019 novel coronavirus (2019-nCoV) by real-**  
527 **time RT-PCR.** *Euro Surveill* 2020, **25**(3).
- 528 9. Smyrlaki I, Ekman M, Lentini A, Rufino de Sousa N, Papanicolaou N, Vondracek M, Aarum J,  
529 Safari H, Muradrasoli S, Rothfuchs AG *et al*: **Massive and rapid COVID-19 testing is feasible**  
530 **by extraction-free SARS-CoV-2 RT-PCR.** *Nat Commun* 2020, **11**(1):4812.
- 531 10. Vogels CBF, Brito AF, Wyllie AL, Fauver JR, Ott IM, Kalinich CC, Petrone ME, Casanovas-  
532 Massana A, Catherine Muenker M, Moore AJ *et al*: **Analytical sensitivity and efficiency**  
533 **comparisons of SARS-CoV-2 RT-qPCR primer-probe sets.** *Nat Microbiol* 2020, **5**(10):1299-  
534 1305.
- 535 11. Kim D, Lee JY, Yang JS, Kim JW, Kim VN, Chang H: **The Architecture of SARS-CoV-2**  
536 **Transcriptome.** *Cell* 2020, **181**(4):914-921 e910.
- 537 12. Viehweger A, Krautwurst S, Lamkiewicz K, Madhugiri R, Ziebuhr J, Holzer M, Marz M: **Direct**  
538 **RNA nanopore sequencing of full-length coronavirus genomes provides novel insights into**  
539 **structural variants and enables modification analysis.** *Genome Res* 2019, **29**(9):1545-1554.
- 540 13. Snijder EJ, Decroly E, Ziebuhr J: **The Nonstructural Proteins Directing Coronavirus RNA**  
541 **Synthesis and Processing.** *Adv Virus Res* 2016, **96**:59-126.
- 542 14. Rajapakse N, Dixit D: **Human and novel coronavirus infections in children: a review.** *Paediatr*  
543 *Int Child Health* 2020:1-20.

- 544 15. Gale C, Quigley MA, Placzek A, Knight M, Ladhani S, Draper ES, Sharkey D, Doherty C, Mactier  
 545 H, Kurinczuk JJ: **Characteristics and outcomes of neonatal SARS-CoV-2 infection in the UK: a**  
 546 **prospective national cohort study using active surveillance.** *The Lancet Child & Adolescent*  
 547 *Health.*  
 548 16. Weisberg SP, Connors TJ, Zhu Y, Baldwin MR, Lin WH, Wontakal S, Szabo PA, Wells SB, Dogra  
 549 P, Gray J *et al*: **Distinct antibody responses to SARS-CoV-2 in children and adults across the**  
 550 **COVID-19 clinical spectrum.** *Nat Immunol* 2020.  
 551 17. Stecher G, Tamura K, Kumar S: **Molecular Evolutionary Genetics Analysis (MEGA) for**  
 552 **macOS.** *Mol Biol Evol* 2020, **37**(4):1237-1239.


553

554 **Figures and Figure Legends**

Age-group-dependent 7-days-incidence in Germany between weeks 10 to 49 (2020)



556 **Figure 1.** 7-days incidence development in Germany between 2020 calendar weeks 10-49. According  
 557 to the laboratory confirmed SARS-CoV-2 case numbers continuously reported by the Robert-Koch-  
 558 Institute ([www.RKI.de](http://www.RKI.de)) the 7-days-incidence for pediatric infections increased very reminiscent of  
 559 most other age-groups. At least for the age groups between 0-14 years, this development contrasts the  
 560 spring situation, when these children were less affected than other age-groups.



561

562 **Figure 2.** Comparison of homologous protein sequence segments (A.) and corresponding cDNA

563 segments (B.) between human coronaviruses. A. We applied the Clustal W algorithm of MEGA [17]

564 to conduct multiple-sequence alignments using the translated protein sequences of the SARS-CoV-2

565 Spike (S) glycoprotein and homologous S protein sequences from other human coronaviruses. Here, a

566 segment harboring polybasic cleavage motif (Q644 to T720 with respect to SARS-CoV-2 S protein).

567 The highlighted residues are conserved in most human coronavirus (black shaded) or are similar

568 between some human coronaviruses (grey shaded). The colored boxes are framing residues, which

569 correspond to the target position of tested oligonucleotides: forward primer (red), probe/sequencing

570 primer (blue), reverse primer (magenta). B. The aligned protein sequences were backtranslated into the

571 encoding cDNA sequences. Similarly, as described above for protein sequences, black or grey shading

572 was used to illustrate identical or similar nucleotide positions. For combined RT-qPCR and


573 pyrosequencing, we selected the following marked sequences for oligonucleotide design: 1. Forward

574 primer (red box/arrow); 2. TaqMan probe with 5'-HEX and 3'-BBQ-650 modifications (blue

575 box/line); 3. Sequencing primer without end-modification (blue box – same sequence as TaqMan

576 Probe); 4. Reverse primer with 5'-Biotin-TEG (magenta box/arrow).

577



578


579 **Figure 3. Comparative characterization of RT-qPCR efficiency and sensitivity.** The same clinical

580 specimen was used for all tests. **A.** The S-gene amplicon (S) was compared with ORF E (E) in

581 singleplex and duplex reactions, respectively. **B.** The direct performance comparison of ORF E (E)

582 amplicons with ORF N (N) and RdRP (R) demonstrated the differences in sensitivity, whereby

583  $E > N > R$ .



585 **Figure 4. Comparative characterization of pyrosequencing sensitivity and basecalling quality.**

586 Serial dilutions of the same clinical specimen were used for all tests. **Top.** Targeted region and

587 principle of S-gene fragment pyrosequencing. Limited by the used PCR primers the maximum

588 theoretical sequence length is 55 nt. **Bottom left.** Resulting pyrograms from serial template dilutions

589 used for RT-qPCR in singleplex reactions and subsequent pyrosequencing of the S-gene amplicons

590 using the antisense single-strand (as defined by the biotinylated reverse primer [S<sub>pb</sub>c-CoV-2-R<sub>BIO</sub>]) are

591 shown. From the undiluted singleplex reaction we obtained the longest unbiased SARS-CoV-2-

592 specific sequence fragment, which had an error-free length of 53 nt. **Bottom right.** Resulting

593 pyrograms from serial template dilutions used for RT-qPCR in duplex reactions and subsequent

594 pyrosequencing of the S-gene amplicons using the antisense single-strand (as defined by the

595 biotinylated reverse primer [S<sub>pb</sub>c-CoV-2-R<sub>BIO</sub>]) are shown. From the undiluted duplex reaction we

596 obtained a maximum unbiased SARS-CoV-2-specific sequence fragment of 44 nt in length. **Bottom**

597 **left/right.** The associated C<sub>T</sub> values are shown besides the degree of dilution. Lower template



598 concentrations led to the occasional occurrence of miscalled bases (missing bases: red triangle; excess  
599 bases: blue triangle) and gradual convergence of signal and noise peaks. Whereas concomitantly,  
600 automated basecalling gradually failed to separate signal from noise, the SARS-CoV-2 specific  
601 sequence could be identified by manual inspection much longer.

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619 **Supplemental information: Combined RT-qPCR and Pyrosequencing of a SARS-CoV-2 Spike**  
620 **Glycoprotein Polybasic Cleavage Motif Uncovers Rare Pediatric COVID-19 Spectrum Diseases**  
621 **of Unusual Presentation**

622 Patrick Philipp Weil<sup>1</sup>, Jacqueline Hentschel<sup>1</sup>, Frank Schult<sup>2</sup>, Anton Pembaur<sup>1</sup>, Beniam Ghebremedhin<sup>3</sup>,  
623 Olivier Mboma<sup>2</sup>, Andreas Heusch<sup>2</sup>, Anna-Christin Reuter<sup>1</sup>, Daniel Müller<sup>1</sup>, Stefan Wirth<sup>2</sup>, Malik  
624 Aydin<sup>4</sup>, Andreas C. W. Jenke<sup>5</sup>, Jan Postberg<sup>1,†</sup>

625 †corresponding author

626

627 <sup>1</sup>Clinical Molecular Genetics and Epigenetics, Faculty of Health, Centre for Biomedical Education &  
628 Research (ZBAF), Witten/Herdecke University, Alfred-Herrhausen-Str. 50, 58448 Witten, Germany

629 <sup>2</sup>HELIOS University Hospital Wuppertal, Children's Hospital, Centre for Clinical & Translational  
630 Research (CCTR), Witten/Herdecke University, Heusnerstr. 40, 42283 Wuppertal, Germany

631 <sup>3</sup>HELIOS University Hospital Wuppertal, Institute of Medical Laboratory Diagnostics, Centre for  
632 Clinical & Translational Research (CCTR), Witten/Herdecke University, Heusnerstr. 40, 42283  
633 Wuppertal, Germany

634 <sup>4</sup>HELIOS University Hospital Wuppertal, Experimental Pediatric Pneumology and Allergology,  
635 Children's Hospital, Centre for Clinical & Translational Research (CCTR), Witten/Herdecke  
636 University, Heusnerstr. 40, 42283 Wuppertal, Germany Sie durch und er das hier

637 <sup>5</sup>Klinikum Kassel, Zentrum für Kinder- und Jugendmedizin, Neonatologie und allgemeine Pädiatrie,  
638 Mönchebergstr. 41-43, 34125 Kassel, Germany

639

640 **The supplemental information contains 1 Table and 4 Figures.**

641


642

<b>Amplicon target</b>	<b>Oligo name</b>	<b>Sequence</b>	<b>Modification</b>	<b>Purpose</b>
<b>S-gene</b>	S <sub>pb</sub> c-CoV-2-F	GCAGGCTGTTTAATAGGGGC	none	Forward primer
	S <sub>pb</sub> c-CoV-2-R <sub>BIO</sub>	ACCAAGTGACATAGTGTAGGCA	5'-biotin-TEG	Reverse primer
	S <sub>pb</sub> c-CoV-2-P	ATTGGTGCAGGTATATGCGCTAGTTATC	5'-HEX, 3'-BBQ-650	Probe
	S <sub>pb</sub> c-CoV-2-S	ATTGGTGCAGGTATATGCGCTAGTTATC	none	Sequencing primer
<b>RdRP (Orf1b)</b>	RdRP_SARSr-F [8]	GTGARATGGTCATGTGTGGCGG	none	Forward primer
	RdRP_SARSr-R [8]	CARATGTTAAASACACTATTAGCATA	none	Reverse primer
	RdRP_SARSr-P2 [8]	CAGGTGGAACCTCATCAGGAGATGC	5'-FAM, 3'-BBQ-650	Probe
<b>Orf E</b>	E_Sarbeco_F [8]	ACAGGTACGTTAATAGTTAATAGCGT	none	Forward primer
	E_Sarbeco_R [8]	ATATTGCAGCAGTACGCACACA	none	Reverse primer
	E_Sarbeco_P1 [8]	ACACTAGCCATCCTTACTGCGCTTCG	5'-FAM, 3'-BBQ-650	Probe
<b>Orf N</b>	N_Sarbeco_F [8]	CACATTGGCACCCGCAATC	none	Forward primer
	N_Sarbeco_R [8]	GAGGAACGAGAAGAGGCTTG	none	Reverse primer
	N_Sarbeco_P [8]	ACTTCCTCAAGGAACAACATTGCCA	5'-FAM, 3'-BBQ-650	Probe

643 **Table S1. Oligonucleotides used for RT-qPCR and pyrosequencing.**

644


645



646

647 **Figure S1. Results of semi-quantitative PCR for the performance comparison using GITC-**  
648 **purified RNA or stabilized raw specimens as RT-qPCR substrates.** Four confirmed SARS-CoV-2-  
649 positive specimens (p1 to p4) were used in combination with primer pairs targeting Orf E, RdRP, Orf  
650 N and S-gene amplicons in singleplex qPCR reactions. From GITC-purified templates, amplicons with  
651 the correct size could be amplified from all specimens. Notably, we observed lower molecular weight  
652 byproducts for Orf E PCR. From stabilized raw specimens, in contrast, the Orf E amplicon was not  
653 amplified from none of the four samples. With varying band intensity, amplicons with correct sizes  
654 were amplified from stabilized raw samples for all cases for RdRP and S-gene targets and in some  
655 cases for the Orf N target. However, for unknown reasons, band intensities appeared less stable when  
656 compared with purified RNA samples. Moreover, we observed lower molecular weight byproducts in  
657 some cases.

658



659


660 **Figure S2. Results of semi-quantitative PCR of the SARS-CoV-2 S-gene amplicon. A.** After 36  
661 PCR cycles and subsequent agarose gel electrophoresis the specific 162 bp amplicon corresponding to  
662 the SARS-CoV-2 protein S-gene was visible (red arrow). The gel was loaded with 8 RT-qPCR  
663 samples from confirmed SARS-CoV-2-positive cases (p1 to p8) and 1 negative control (n1). The  
664 occasional weak appearance of PCR byproducts (see p1) seemed to correlate with relatively low viral  
665 (+)RNA load in the specimen. **B.** An excess of PCR cycles (40x) leads to enrichment of unspecific  
666 lower and higher molecular weight byproducts in all samples from confirmed positive samples (p1 to  
667 p9) as well as negative controls (n1 to n3). These byproducts severely impaired the successive  
668 pyrosequencing leading to ambiguous results.

669

670

671


672



673

674 **Figure S3. Results of a triplex PCR approach for the simultaneous detection of amplicon targets**  
 675 **for RdRP, Orf E and Orf N.** For comparison, 14 SARS-CoV-2-negative samples (n1 to n14) and 11  
 676 confirmed SARS-CoV-2-positive specimens were analysed by agarose gel electrophoresis. The  
 677 simultaneous use of primers for RdRP, Orf E and Orf N amplicons leads to enrichment of unspecific  
 678 lower and higher molecular weight byproducts in all samples, confirmed positives as well as  
 679 negatives. Remarkably, in the fraction of negative samples bands of approx. 160 bp appear frequently.

680



681

682 **Figure S4. Presentation of a female toddler (age group 1-3 years) with a Multisystem**  
 683 **Inflammatory Syndrome in Children (MIS-C)/Kawasaki-like syndrome associated with SARS-**  
 684 **CoV-2 infection.** **A.** Echocardiography revealed an enlargement of the left coronary artery (LCA) with  
 685 a pericardial effusion. **B.** Flow cytometric characterization of the peripheral mononuclear blood cells  
 686 resulted in normal ranges of CD3<sup>+</sup> T, CD4<sup>+</sup> T helper, CD19<sup>+</sup> B, and CD16<sup>+</sup>CD56<sup>+</sup> natural killer cells.